Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
Csilla Várnai(University of Birmingham), Jaishree Bhosle, Claire Palles(University of Oxford), Rachel Kerr(Cancer Research UK Clinical Trials Unit), Karin Purshouse(Edinburgh Cancer Research), Tom Newsom‐Davis, Roland Arnold(Cancer Research UK), Heather Shaw, Claire Fuller, Rachel Sharkey(Chelsea and Westminster Hospital), Jack Illingworth, Clare Griffin, Madbuba Choudhury, Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Lennard Y. W. Lee(University of Oxford), Peter S Hall(University of Edinburgh), Austin Kulasekararaj(King's College London), Laura Horsley, Stephen Booth(Royal Berkshire Hospital), Stephen P. Hibbs(Queen Mary University of London), Vinton W.T. Cheng(University of Leeds), Caroline Usbourne, Pippa Corrie(University of Cambridge), Ann Tivey, Naomi Campton, Ana Ferreira, Rohan Shotton, Anna Olsson‐Brown(University Hospitals Sussex NHS Foundation Trust), Duncan C. Gilbert(Royal Sussex County Hospital), Joseph J. Sacco(University of Liverpool), S. Pugh(Addenbrooke's Hospital), Jean‐Baptiste Cazier(University of Oxford), Alvin Lee(Duke Medical Center), Helen Curley(University of Birmingham), Paul Ramage(Novartis (Switzerland)), Madeleine Hewish, Archana Sharma‐Oates(University of Birmingham), Rebecca Lee(Broughton Hospital), Graham P. Collins(Churchill Hospital), Pauline Leonard, Samah Massalha, Ahmed Bedair, Jillian Noble, Rachel Bolton, Simon Shamas, Jennifer Davies, D.J. Hughes(St Thomas' Hospital), Nicolaos Diamantis, Mieke Van Hemelrijck(Ghent University Hospital)
Cited by 59
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Large-scale association analysis identifies new risk loci for coronary artery disease
|Nature Genetics|2012|1.7k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters
|Cell|2016|1.2k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869